Ignite Creation Date:
2024-05-05 @ 12:03 PM
Last Modification Date:
2024-10-26 @ 9:19 AM
Study NCT ID:
NCT00230763
Status:
COMPLETED
Last Update Posted:
2021-02-18
First Post:
2005-09-29
Brief Title:
Determination Of Predictive Factors Allowing To An Additional 10 Reduction Of Intra-Ocular Pressure
Sponsor:
Pfizers Upjohn has merged with Mylan to form Viatris Inc
Organization:
Pfizer
Study Overview
Official Title:
Determination Of Predictive Factors Allowing To An Additional 10 Reduction Of Intra-Ocular Pressure After A 12-Week Treatment With Latanoprost 0005 Timolol 05 Fixed Combination Xalacom In Previously Treated Patients With Open Angle Glaucoma Or Ocular Hypertension
Status:
COMPLETED
Status Verified Date:
2015-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
PREDICOM
Brief Summary:
To determine the predictive factors of a positive response to latanoprost 0005 timolol 05 fixed combination defined as a 10 IOP reduction from baseline after 12 weeks of treatment age sex ethnic origin patients medical history family history of OAG or OHT concomitant systemic treatment with beta-blockers etiology IOP at baseline corneal thickness compliance and adverse events
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None